Peter Sguigna, M.D. Assistant Professor School Medical School Department Neurology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Joined UT Southwestern: 2020 Clinical Interests: Dr. Sguigna specializes in multiple sclerosis and related disorders. He sees patients with multiple sclerosis, optic neuritis, and other neuro-immunological disorders. He has clinical interest in those patients with neurological disease that have prominent visual symptoms or findings. Research: Dr. Sguigna's research interests and activities include advanced diagnostic imaging of neuro-ophthalmological disorders, as well as unraveling the neuro-retinal circuitry in neuroimmunological diseases. He actively works on better ways to distinguish these disorders using non-invasive technology. He uses specialized testing to gain insight into some of the most disabling symptoms for patients with multiple sclerosis. He leads multiple clinical trials for patients with multiple sclerosis to reduce disability, as well as symptoms such as fatigue and word finding difficulty. Trainee Education: Dr. Sguigna provides education to medical students, residents, and fellows rotating through his clinic and research laboratory. Occasionally he will invite high school students and undergraduate students for rotations, as education is a prominent goal of the department. Education Medical School UT Southwestern Medical School (2014) Residency UT Southwestern Medical Center (2018), Neurology Fellowship UT Southwestern Medical Center (2020), Multiple Sclerosis Research Interest Clinical Treatment Trials Medical Devices MOG Antibody Associated Disorders Multiple Sclerosis Neuro-Ophthalmology Neuromyelitis Optica Spectrum Disorder Optic Neuritis Visual Dysfunction Publications Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z) Ren J, Dewey RB, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2024 Dec 22 Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17 Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials Ren J, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2023 Dec 21 Subclinical optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease Nguyen L, Wang CX, Conger DL, Sguigna PV, Singh S, Greenberg BM Multiple Sclerosis and Related Disorders 2023 Aug 76 A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis Tardo L, Salter A, Truong-Le M, Horton L, Blackburn KM, Sguigna PV Therapeutic Advances in Chronic Disease 2023 Jan 14 Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study Sguigna PV, Toranian S, Tardo LM, Blackburn KM, Horton LA, Conger D, Meltzer E, Hogan RN, McCreary M, Zee PC, Takahashi JS, Greenberg BM Multiple Sclerosis Journal - Experimental, Translational and Clinical 2023 Jan 9 A cross-sectional natural history study of aspartylglucosaminuria Goodspeed K, Horton DK, Lowden A, Sguigna PV, Booth T, Wang ZJ, Edgar VB JIMD Reports 2022 Sep 63 425-433 The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives Hussain RZ, Sguigna PV, Okai A, Wright C, Madinawala M, Bass AD, Cutter GR, Manouchehri N, Stuve O Journal of Central Nervous System Disease 2022 Aug 14 Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience Sguigna PV, Tardo LM, Blackburn KM, Horton LA, Conger DL, Hogan RN, McCreary MC, Greenberg BM Neuro-Ophthalmology 2022 46 375-382 Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus Sguigna PV, Tardo L, Conger D, Hogan R, Greenberg BM Journal of the Neurological Sciences 2021 Nov 430 Results 1-10 of 19 1 2 Next Last